Home › Companies › VNDA

Vanda Pharmaceuticals

VNDA Rare disease Lead: Approved 10 Biotech Distilled articles ↓

Cardiovascular Dermatology GI/Hepatology Hematology Immunology Infectious Disease Neurology Ophthalmology Nucleic Acid Protein Small Molecule

Most recent annual filing: 2026-02-13

Catalyst timeline

4 trackedQuarter catalyst calendar →

HETLIOZ® litigation rulingOct 26, 2026HETLIOZ® litigation ruling, Oct 26, 2026, notable
Jet Lag patent litigation rulingDec 2026Jet Lag patent litigation ruling, Dec 2026, routine
Imsidolimab FDA approvalDec 12, 2026Imsidolimab FDA approval, Dec 12, 2026, material
Bysanti™ milsaperidone readout1H 2027Bysanti™ milsaperidone readout, 1H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (29 active programs)

Fanapt

iloperidone

Schizophrenia Approved oral
Bipolar I Disorder Approved oral NCT02413918
Schizophrenia Phase 3 intramuscular
Hypertension Phase 1 intramuscular NCT07090161

HETLIOZ

tasimelteon

Small Molecule Target: MT1, MT2

Non-24-Hour Sleep-Wake Disorder Approved oral NCT01163032
Smith-Magenis Syndrome Approved oral NCT02231008
Jet Lag Disorder NDA Submitted oral NCT03291041
Insomnia NDA Submitted oral NCT03373201
Delayed Sleep Phase Disorder Phase 3 oral

PONVORY

ponesimod

Psoriasis Phase 3 oral NCT07362017
Ulcerative Colitis Phase 3 oral NCT07686081
Relapsing Multiple Sclerosis Approved oral

NEREUS

tradipitant

Small Molecule Target: GLP-1 receptor

Motion Sickness Approved oral Eli Lilly and Company NCT03772340
Nausea and Vomiting Phase 3 oral Eli Lilly NCT07446439
Gastroparesis NDA Submitted oral Eli Lilly and Company NCT02970968
Atopic Dermatitis Phase 3 oral Eli Lilly NCT02651714

Bysanti

milsaperidone

Bipolar I Disorder Approved oral
Schizophrenia Approved oral
Major Depressive Disorder Phase 3 oral NCT06830044

Quimilza

imsidolimab

Protein Target: IL-36R, IL-36 receptor

Generalized Pustular Psoriasis NDA Submitted AnaptysBio NCT03619902

VTR-297

Small Molecule Target: HDAC

Onychomycosis Phase 1

VSJ-110

Small Molecule Target: CFTR

Dry Eye Disease Phase 1 University of California San Francisco NCT06296966
Ocular Inflammation University of California San Francisco

VPO-227

Small Molecule Target: CFTR

Cholera Phase 1 oral University of California San Francisco
Secretory Diarrhea University of California San Francisco

VQW-765

Small Molecule Target: alpha-7 nicotinic acetylcholine receptor

Social Anxiety Disorder Phase 3 Novartis NCT04800237

VCA-894A

Nucleic Acid Target: IGHMBP2

Charcot-Marie-Tooth Disease Type 2S Phase 1 OliPass NCT07223632

VGT-1849A

Polycythemia Vera Preclinical OliPass

VGA-157A

Parkinson's Disease

Biotech Distilled coverage (10)

2026-08-06 UPDATE: Vanda Pharmaceuticals (VNDA) - The HETLIOZ® Cliff Arrives 🔒 Paid
2026-05-06 UPDATE: Vanda Pharmaceuticals (VNDA) — The Burn Rate Confession and the DTC Hail Mary
2026-03-21 UPDATE: Vanda’s $30 Million "Ethics" Play — Turning the Tradipitant Roadblock into a PR War 🔒 Paid
2026-03-07 UPDATE: Vanda’s (VNDA) Litigation Moat Makes History — The 40-Year FDA Streak is Broken 🔒 Paid
2026-02-28 UPDATE: Vanda Pharmaceuticals (VNDA) - The Narrative Machine Speeds Up 🔒 Paid
2026-02-21 UPDATE: Vanda Pharmaceuticals (VNDA) - The PDUFA Pop Arrives — Now Watch for the Anvil 🔒 Paid
2026-02-14 UPDATE: Vanda Pharmaceuticals (VNDA) - The Dilution Gap Confirmed — Vanda Drops a $200M Shelf 🔒 Paid
2026-02-11 UPDATE: Vanda Pharmaceuticals (VNDA) Expensive Victory Lap — NEREUS™ Approved, Cash Burn Accelerates 🔒 Paid
2026-01-10 UPDATE: Vanda vs. The FDA (Round Infinity) — The Jet Lag Denial 🔒 Paid
2025-12-31 FDA APPROVED Dec. 30, 2025 :: Vanda Pharmaceuticals (VNDA): Scientific Due Diligence for Tradipitant and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.